Article

Metabolomic Signatures of Brain Atrophy and Ibudilast Response in Progressive Multiple Sclerosis

2026-05-26

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> Progressive multiple sclerosis (MS) is characterized by ongoing neurodegeneration and limited therapeutic options. Circulating metabolites provide insight into disease biology, yet biomarkers that predict disability progression and reflect treatment response are lacking. We aimed to identify metabolomic signatures associated with longitudinal MRI measures of brain atrophy and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 55f4adf1-036f-5bdf-8b72-28267fa200a9
DOI: 10.64898/2026.05.21.26353780

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Metabolomic Signatures of Brain Atrophy and Ibudilast Response in Progressive Multiple SclerosisDOI 10.64898/2026.05.21.26353780Read

Metabolomics reveals lipid and amino acid signatures of disease severity in multiple sclerosisSemantic proximity Read

Metabolomic and Lipid Alterations are Associated with Longitudinal Neurological Performance in Multiple SclerosisSemantic proximity Read

MS Atlas - A molecular map of brain lesion stages in progressive multiple sclerosisSemantic proximity Read

Utility of an untargeted metabolomics approach using a 2D GC-GC-MS platform to distinguish relapsing and progressive multiple sclerosisSemantic proximity Read

Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosisSemantic proximity Read

CSF metabolites associated with biomarkers of Alzheimer’s disease pathologySemantic proximity Read

Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosisSemantic proximity Read

Molecular mechanisms associated with multiple sclerosis progression, severity and phenotypeSemantic proximity Read

Utility of an untargeted metabolomics approach using a 2D GC-GC‒MS platform to distinguish relapsing and progressive multiple sclerosisSemantic proximity Read

Biochemical and metabolic maladaption defines pathological niches in progressive multiple sclerosisSemantic proximity Read

Multi-omic Evaluation of Metabolic Alterations in Multiple Sclerosis Identifies Shifts in Aromatic Amino Acid MetabolismSemantic proximity Read

Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer’s Disease Neuroimaging Initiative cohortSemantic proximity Read